Indaptus Therapeutics' Chief Scientific Officer to Present at Donor Selection & Cell Source Summit, Highlighting Decoy Bacteria Platform for Allogeneic Immune Cell Cancer Therapy.
ByAinvest
Monday, Nov 17, 2025 8:02 am ET1min read
INDP--
Indaptus Therapeutics' Chief Scientific Officer, Dr. Michael Newman, will present at the 3rd Donor Selection & Cell Source Summit. The presentation will highlight the company's Decoy bacterial platform, which uses killed, multi-immune agonist bacteria to trigger a broad immune response and address donor cell variability in allogeneic immune cell cancer therapy. The platform has the potential to enhance the potency and reproducibility of donor-derived cell therapies.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet